News Archive

DSM provides Q1 2023 trading update | DSM

Prioritising profitability over sales volumes has supported our margins, which improved sequentially into the first quarter.”

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM agrees terms to acquire postbiotics pioneer Adare Biome

DSM announces that it has entered into exclusive negotiations with Adare Pharma Solutions in order to acquire Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million. This transaction represents an estimated 2023 EV/EBITDA multiple of 18x.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM completes sale of Engineering Materials business

Royal DSM announces the completion of the sale of its Engineering Materials business to Advent International and LANXESS for an Enterprise Value of €3.85 billion.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Large scale pilot proves methane-reducing feed additive Bovaer® is ready for roll-out in the Netherlands

Dutch dairy company Royal FrieslandCampina, DSM, and feed supplier Agrifirm have successfully incorporated Bovaer® into the regular farming activities of 158 dairy farms in the Netherlands in the world’s first large-scale on-farm use of the methane-reducing feed additive for cattle.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM quantifies food system impact

DSM reveals the first audited results of its progress in helping to address urgent societal and environmental challenges linked to how the world produces and consumes food.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM publishes Integrated Annual Report 2022 | DSM

Royal DSM, a global purpose-led, performance-driven leader in Health, Nutrition & Bioscience, today announces the publication of its 2022 Integrated Annual Report (IAR).

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM reports 2022 results

DSM delivered a solid performance in 2022 against a background of continued global supply chain challenges and significantly higher energy and raw materials costs, consolidating the strong growth of 2021. Pricing actions to counter higher costs, supported top-line growth, however with a price-cost gap impacting near-term margins, especially in Animal, Nutrition & Health.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM shareholders approve DSM-Firmenich merger at EGM | DSM

DSM today held an Extraordinary General Meeting of Shareholders (EGM). The DSM Shareholders approved the proposed merger between DSM and Firmenich International SA (Firmenich) and voted in favour of all related resolutions as set out in the notice of the EGM.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares 

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules.

DSM starts construction of production facility for its novel Bovaer® methane-reducing feed in Dalry

The plant will significantly increase global production of Bovaer®, DSM’s unique methane-reducing feed additive for cattle. In an official groundbreaking ceremony attended by the First Minister of Scotland, Nicola Sturgeon, and Dimitri de Vreeze, Co-CEO of DSM, the company marked the next step in its plan to use Bovaer® to reduce global methane emissions and contribute to worldwide methane reduction targets.

Science Based Targets initiative validates DSM’s ambition to reduce direct greenhouse gas emissions as 1.5°C aligned

DSM confirms that its target to cut scope 1 and 2 greenhouse gas (GHG) emissions has been determined to be in line with the latest climate science and in keeping global warming to no more than 1.5°C by the Science Based Targets initiative (SBTi).

DSM provides Q3 2022 trading update

DSM’s trading update for the first nine months of 2022 is out now and our Health, Nutrition & Bioscience businesses all delivered good sales growth. Market demand remained resilient in what is a challenging macro-economic environment with the rising cost inflation.

DSM completes acquisition of Prodap

DSM today announces the completion of its acquisition of Prodap, a leading animal nutrition and technology company in Brazil.

DSM completes sale of Protective Materials business

DSM, a global purpose-led science-based company, today announces the completion of the sale of its Protective Materials business to Avient Corporation

DSM reports H1 2022 results

A good half year performance underpinned by resilient market demand.

DSM sets new climate targets to accelerate route to net-zero

DSM announces that it pledges to purchase all of its electricity worldwide from renewable sources

DSM provides 2021 and 2022 Q1 comparative figures

Royal DSM, a global purpose-led science-based company, today provides the investment community with comparative quarterly figures for 2021 and 2022 Q1.

DSM acquires Brazil’s leading animal nutrition technology company to boost precision services offering

Royal DSM, a global purpose-led science-based company, announces it has reached an agreement to acquire Prodap, a Brazilian animal nutrition and technology company that combines technology offerings, consulting services, and customized nutritional solutions to drive efficiency and sustainability in animal farming.

DSM announces sale of Engineering Materials business

Royal DSM, a global purpose-led science-based company, today announces that it has reached an agreement to sell its Engineering Materials business to Advent International and LANXESS for an Enterprise Value of €3.85 billion.

DSM and the World Food Programme partner to improve nutrition around the world

Royal DSM and the World Food Programme (WFP) have agreed to extend their partnership and scale up rice fortification worldwide for a further three years. The partnership will seek to improve the availability and accessibility of nutritious foods in order to reach vulnerable people where key dietary decisions are made.

Final dividend 2021 Royal DSM

Royal DSM, a global purpose-led science-based company, confirmed its resolution to declare a dividend for the financial year 2021 of €2.50 per ordinary share was passed today, 10 May 2022, at its Annual General Meeting of Shareholders.

DSM announces results of 2022 Annual General Meeting of Shareholders

Royal DSM, a global purpose-led science-based company, today held its Annual General Meeting of Shareholders. All the resolutions on the agenda were approved by the shareholders.

DSM, UNICEF and Sight and Life extend global partnership to address malnutrition at scale

Royal DSM, a global purpose-led science-based company, the United Nations’ children’s agency UNICEF, and Swiss-based nutrition think tank and incubator Sight and Life have renewed their long-term partnership to deliver better nutrition for at-risk groups in countries in Sub-Saharan Africa and Asia.

DSM - repurchase of shares (2-6 May 2022)

Royal DSM, a global purpose-led science-based company, has repurchased 40,085 of its own shares in the period from 2 May 2022 up to and including 6 May 2022 at an average price of €156.08.

DSM - repurchase of shares (25-29 April 2022)

Royal DSM, a global purpose-led science-based company, has repurchased 157,671 of its own shares in the period from 25 April 2022 up to and including 29 April 2022 at an average price of €156.34.

DSM provides Q1 2022 trading update

DSM delivered a good first quarter.

Elanco and Royal DSM Announce Strategic Alliance in U.S. for Bovaer® – A Revolutionary, Methane-Reducing Feed Additive for Cattle

Elanco Animal Health Incorporated (ELAN: NYSE) and Royal DSM have created a strategic alliance connecting two leading, sustainability-focused companies to address one of society’s most significant opportunities of the decade, mitigating climate change by reducing greenhouse gas emissions from farming. Elanco has secured the exclusive U.S. licensing rights to develop, manufacture and commercialize Bovaer® for beef and dairy cattle.

DSM - repurchase of shares (18-22 April 2022)

Royal DSM, a global purpose-led science-based company, has repurchased 142,403 of its own shares in the period from 18 April 2022 up to and including 22 April 2022 at an average price of €155.73.

Arla Foods and DSM start large-scale on-farm pilot to reduce greenhouse gas emissions from dairy cows by 30%

European dairy cooperative Arla Foods and global purpose-led science-based company, Royal DSM, are set to start a large-scale on-farm pilot with the methane reducing feed additive Bovaer® on 10,000 dairy cows across three European countries.

DSM - repurchase of shares (11- 15 April 2022)

Royal DSM, a global purpose-led science-based company, has repurchased 101,258 of its own shares in the period from 11 April 2022 up to and including 15 April 2022 at an average price of €158.07.

DSM announces sale of Protective Materials business

Royal DSM, a global purpose-led science-based company, today announces that it has reached an agreement to sell its Protective Materials business to Avient Corporation for an Enterprise Value of €1.44 billion.

DSM - repurchase of shares (4- 8 April 2022)

Royal DSM, a global purpose-led science-based company, has repurchased 173,491 of its own shares in the period from 4 April 2022 up to and including 8 April 2022 at an average price of €162.36.

DSM - repurchase of shares (28 March-1 April 2022)

Royal DSM, a global purpose-led science-based company, has repurchased 171,521 of its own shares in the period from 28 March 2022 up to and including 1 April 2022 at an average price of €162.39.

DSM provides preliminary 2021 comparative figures

Royal DSM, a global purpose-led science-based company, today provides preliminary comparative financial figures for 2021 following the establishment of DSM’s Health, Nutrition & Bioscience (“HNB”) structure, which became effective as of 1 January 2022.

DSM - repurchase of shares (21-25 March 2022)

Royal DSM, a global purpose-led science-based company, has repurchased 205,518 of its own shares in the period from 21 March 2022 up to and including 25 March 2022 at an average price of €160.28.

FrieslandCampina and DSM take major step to reduce greenhouse gas emissions from dairy cattle

The Bovaer® pilot collaboration between the Dutch companies FrieslandCampina, DSM, and Agrifirm marks an important step forward in increasing the sustainability of the dairy sector. Some 200 FrieslandCampina dairy farms in the Netherlands will take part in the pilot in the second half of 2022. Providing the results are positive, the use of Bovaer® will be further upscaled from 2023.

DSM - repurchase of shares (14- 18 March 2022)

Update March 22nd: DSM has repurchased 176,083 of its own shares in the period from 10 March 2022 up to and including 11 March 2022 at an average price of €150.87.

DSM - repurchase of shares (10-11 March 2022)

DSM has repurchased 176,083 of its own shares in the period from 10 March 2022 up to and including 11 March 2022 at an average price of €150.87.

DSM announces repurchase of shares to cover share plans and stock dividend

Royal DSM, a global purpose-led science-based company, today announces the repurchase, starting 10 March 2022, of 1,330,000 ordinary shares.

DSM publishes 2021 Integrated Annual Report

DSM publishes 2021 annual report on the company's social, environmental and financial performance for the year.

DSM receives landmark EU market approval for its methane-reducing feed additive Bovaer®

Royal DSM, a global purpose-led science-based company, announces that European Union (EU) member states approved the marketing of the methane-reducing feed additive for dairy cows, Bovaer®, in the EU. After inclusion in the EU registry, expected in the coming weeks, it is the first time a feed additive authorised in the EU for environmental benefits can be marketed. This marks a significant milestone for DSM, paving the way for Bovaer® to revolutionize the dairy market.

DSM reports 2021 results

Strong financial growth alongside significant progress toward our sustainability and strategy ambitions made 2021 a year to be proud of.

DSM completes the acquisition of Vestkorn Milling

Royal DSM, a global purpose-led science-based company, today announces the completion of its acquisition of Vestkorn Milling for an enterprise value of €65m. This acquisition of one of Europe’s leading producers of pea- and bean-derived ingredients for plant-based protein products was first announced on 29 November 2021.

DSM to acquire Vestkorn Milling to accelerate growth in plant-based proteins

Royal DSM, a global purpose-led science-based company, announces today that it has signed an agreement to acquire Norwegian company Vestkorn Milling, one of Europe’s leading producers of pea- and bean-derived ingredients for plant-based protein products, for an enterprise value of €65m.

DSM receives positive EFSA opinion for methane-reducing feed additive Bovaer®

DSM has received a positive European Food Safety Authority (EFSA) opinion for the use of its novel methane-reducing feed additive for ruminants, Bovaer®, in the European Union. The EFSA opinion confirms that the feed additive reduces enteric methane emissions from dairy cows and is safe for the animal and the consumer.

DSM plans new production site for Bovaer® in Dalry, Scotland

DSM is planning to realize large scale production capacity for its novel methane-reducing feed additive for ruminants, Bovaer® with a new plant at its existing site in Dalry, Scotland, supported by Scottish Enterprise.

DSM provides first nine months 2021 trading update

DSM delivers a very good nine months of the year.

DSM completes the acquisition of First Choice Ingredients

DSM acquires First Choice Ingredients, a leading supplier of dairy-based savory flavorings.

DSM announces food system commitments to set a healthier future for people, planet and livelihoods

Quantifiable commitments aim to address how the world produces and consumes food by 2030.

DSM accelerates its strategic journey to a fully focused Health, Nutrition & Bioscience company

DSM is simplifying its operating structure and reorganizing its Health, Nutrition & Bioscience activities into three Business Groups.

DSM sites in Jiangsu Province, China in first group to sign Renewable Energy Power Purchase Agreements

The four plants will become among the first in the province to run on renewable energy.

DSM to acquire First Choice Ingredients to accelerate growth in food and beverage

DSM to acquire developer of clean label, fermented dairy and dairy-based savory flavorings for taste and functional solutions.

DSM - repurchase of shares (23-27 Aug 2021)

DSM has completed the repurchase 250,000 shares announced on 9 August 2021 for a total consideration of €44.6 million.

DSM - repurchase of shares (16-20 Aug 2021)

DSM repurchased 109,792 shares from 16 to 20 August 2021 at an average price of €178.66.

DSM - repurchase of shares (9-13 Aug 2021)

DSM repurchased 80,268 shares from 9 to 13 August 2021 at an average price of €175.75.

DSM to be powered by 100% renewable electricity in North America by the end of 2021

New Power Purchase Agreement (PPA) will dramatically reduce DSM's CO2 emissions by approximately 50,000 tons/year.

DSM announces repurchase of shares to cover stock dividend

DSM will repurchase 250,000 ordinary shares to cover commitments for the interim stock dividend 2021.

DSM accelerates science based GHG emissions reduction target to 50% by 2030

DSM accelerates its 30% greenhouse gas (GHG) emissions reduction target to 50% by 2030.

DSM reports H1 2021 results

DSM delivers very good first half year results, with full year outlook updated to reflect stronger Materials performance.

DSM acquires next-generation eubiotics platform start-up

DSM acquires biotech start-up Midori, developers of breakthrough eubiotics for more sustainable animal farming.

DSM’s global head office to move to Maastricht, the Netherlands

New office to exemplify DSM’s culture and philosophy of hybrid working and be an inspiring environment for people to connect and collaborate.

DSM informs market on the announced sale of AOC to Lone Star Funds affiliate

DSM informs its stakeholders that CVC Capital Partners today announced the proposed sale of AOC.

DSM - repurchase of shares (14-15 June 2021)

DSM has completed the repurchase of 800,000 of its own shares at an average price of €150.36.

DSM concludes early redemption of €500 million bond

€500 million 1.375% bond originally due to mature in September 2022 redeemed early.

DSM - repurchase of shares (7-11 June 2021)

DSM repurchased 66,456 shares from 7 to 11 June 2021 at an average price of €152.02.

DSM - repurchase of shares (31 May - 4 June 2021)

DSM repurchased 117,895 shares from 31 May to 4 June 2021 at an average price of €151.73.

DSM completes sale of DSM Advanced Solar backsheets business to Worthen Industries, Inc.

Sale completes divestment of all DSM’s solar activities.

DSM - repurchase of shares (24-28 May 2021)

DSM repurchased 102,721 shares from 24 to 28 May 2021 at an average price of €151.13.

DSM - repurchase of shares (17-21 May 2021)

DSM repurchased 126,930 shares from 17 to 21 May 2021 at an average price of €148.27.

DSM announces early redemption of €500 million bond

€500 million 1.375% bond issued 24 September 2015 to be redeemed earlier than scheduled.

DSM - repurchase of shares (10-14 May 2021)

DSM repurchased 145,703 shares from 10 to 14 May 2021 at an average price of €147.94.

DSM launches cycling challenge series to encourage people to improve their health through exercise and nutrition

Get on your bike for the DSM Keep Challenging Series. Sign-up now!

DSM - repurchase of shares (3-7 May 2021)

DSM repurchased 192,978 shares from 3 to 7 May 2021 at an average price of €151.32.

Dutch PPE Solutions starts large-scale production of filter material for medical facemasks

Joint venture is first to deliver professional facemasks with filter material made entirely on Dutch soil.

Final dividend 2020 Royal DSM

DSM declares a dividend for the 2020 financial year of €2.40 per ordinary share.

DSM announces results of 2021 Annual General Meeting of Shareholders

DSM held a virtual Annual General Meeting of Shareholders on 6 May 2021 when shareholders approved all resolutions on the agenda.

Annual General Meeting of Shareholders 2021

Summary of the resolutions and voting at DSM's most recent Annual General Meeting of Shareholders held virtually on 6 May 2021.

DSM provides Q1 2021 trading update

DSM delivers very good Q1 with sales +7% and adjusted EBITDA +13%, updates Outlook 2021 reflecting strong Materials recovery.

DSM announces cancellation of 6.6m treasury shares to conclude reduction in share capital

Cancellation concludes reduction in share capital following share buyback program executed from 1 April 2019 to February 2020.

DSM completes sale of Resins & Functional Materials businesses

Sale to Covestro agreed in September 2020 for an equity value of €1.6 billion has finalized today.

DSM acquires Flavor & Fragrance bio-based intermediates business from Amyris

DSM acquires business consisting of 7 bio-based intermediate products to add to existing Aroma Ingredients portfolio.

DSM announces repurchase of shares to cover stock dividend

DSM will repurchase 800,000 ordinary shares to cover commitments for the final stock dividend 2020.

DSM announces DSM Advanced Solar backsheets business to be acquired by Worthen Industries, Inc.

DSM to sell residual solar backsheet business to Worthen Industries, Inc. following the sale of its solar coatings business to Covestro.

DSM announces new Supervisory Board Chairman and proposes new Supervisory Board member

Supervisory Board appoints Thomas Leysen to succeed Rob Routs as Chair and proposes Corien M. Wortmann-Kool as a new member.

DSM continues to make strong progress on its People, Planet and Profit ambitions

DSM publishes 2020 annual report on the company's social, environmental and financial performance for the year.

DSM reports 2020 results

DSM posts solid results in a challenging COVID-19 environment, continues to make good progress on execution of long-term strategic plan.

DSM Nutritional Products’ President & CEO Chris Goppelsroeder to retire

Chris Goppelsroeder to retire on 1 April 2021 with DSM's Co-CEO Dimitri de Vreeze stepping into the role.

DSM and TU Delft establish artificial intelligence laboratory to drive bioscience innovation

The Artificial Intelligence Lab for Biosciences first of its kind in Europe to apply artificial intelligence to full-scale biomanufacturing,

In memoriam Hans van Liemt

It is with sadness that we share with you the news of the passing away of our former Managing Board Chairman, Hans van Liemt.

Pro cycling’s newest elite team unveiled - Team DSM

Strategic partnership with Team Sunweb sees professional cycling team transform into Team DSM for 2021 season onwards.

DSM reports results first nine months 2020

DSM reports a solid first nine months in a challenging COVID-19 environment, with a continuing robust performance in Q3.

DSM provides preliminary 2019 and 2020 H1 comparative figures

DSM’s Resins & Functional Materials businesses moved to discontinued operations with their agreed sale to Covestro AG.

DSM completes acquisition of Erber Group

DSM acquires Erber's Biomin specialty animal nutrition and health & Romer Labs food/feed safety diagnostics businesses.

DSM announces sale of Resins & Functional Materials businesses

DSM to sell its Resins & Functional Materials and associated businesses to Covestro AG for an Equity Value of €1.6 billion.

DSM proposes new Supervisory Board member

DSM's Supervisory Board nominates Mrs. Carla Mahieu for appointment as a new Supervisory Board member at next AGM.

Dutch JV to produce facemasks & PPE filter material locally

Partners investing several million €'s on manufacturing equipment and construction of new manufacturing facilities in Netherlands.

DSM - repurchase of shares (24-28 August 2020)

DSM repurchased 27,328 shares from 24 to 28 August 2020 at an average price of €134.92.

DSM - repurchase of shares (17-21 August 2020)

DSM repurchased 70,444 shares from 17 to 21 August 2020 at an average price of €131.13.

DSM - repurchase of shares (7-14 August 2020)

DSM repurchased 102,228 shares from 7 to 14 August 2020 at an average price of €129.61.

DSM announces repurchase of shares to cover stock dividend

Repurchase of 200,000 ordinary shares equivalent to approximately €25 million on 6 August 2020.

DSM reports H1 2020 results

DSM reports a solid H1 2020 in a challenging COVID-19 environment, overall earnings outlook remains suspended.

DSM appoints Cristina Monteiro new EVP People & Organization and member of the Executive Committee

Cristina Monteiro appointed Executive Vice President People & Organization and member of the Executive Committee as of 1 September 2020.

DSM appoints Zhou Tao (Joe) as President DSM China

Zhou Tao (Joe) succeeds Dr. Weiming Jiang as President DSM China as of 1 July 2020.

DSM issues €1 billion long-term bonds to finance acquisition of Erber Group

New bonds in two tranches of €500m allow DSM to lock-in low interest rates to finance the acquisition of the Erber Group.

DSM finalizes share repurchase to cover share plans and stock dividend and cancels remainder of its €1 billion share buy-back

As prudent measure given Covid-19 environment and acquisition of Erber Group, DSM cancels remainder of €1 billion share buy-back program.

DSM to add world-leading animal nutrition and health specialty businesses with acquisition of Erber Group

DSM adds Erber Group’s mycotoxin risk and gut health performance management and food and feed safety diagnostic solutions to portfolio.

Final dividend 2019 Royal DSM

DSM declares a dividend for the financial year 2019 of €2.40 per ordinary share.

DSM announces results of 2020 Annual General Meeting of Shareholders

DSM held a virtual Annual General Meeting of Shareholders on 8 May 2020 when shareholders approved all resolutions on the agenda.

Annual General Meeting of Shareholders 2020

Summary of the resolutions and voting at DSM's Annual General Meeting of Shareholders 2020.

DSM to help accelerate Dutch Covid-19 testing by making 2.8 million nose swabs

DSM will produce sufficient swabs to meet the entire country’s testing needs for the next three months.

DSM reports Q1 2020 results

DSM reports a solid Q1 2020, suspends overall earnings outlook given current limited visibility in Materials.

Production of FFP2 masks begins

Consortium of AFPRO Filters, Auping and DSM has begun large-scale production of FFP2 facemasks for healthcare workers.

DSM firmly on course to achieve 75% renewable electricity with largest PPA partnerships to date

DSM signs largest renewable energy Power Purchase Agreement (PPA) to date.

DSM completes acquisition of Glycom

DSM acquires world's leading supplier of Human Milk Oligosaccharides (HMO) for early life nutrition applications.

DSM Co-CEOs statement on the COVID-19 outbreak

We are humbled by our people’s efforts and want to provide a broader update on how DSM is responding to the constantly evolving situation.

DSM - repurchase of shares (16-20 March 2020)

DSM repurchased 239,127 shares from 16 to 20 March 2020 at an average price of €89.77.

DSM - repurchase of shares (9-13 March 2020)

DSM repurchased 705,494 shares from 9 to 13 March 2020 at an average price of €96.33.

DSM - repurchase of shares (2-6 March 2020)

DSM repurchased 455,379 shares from 2 to 6 March 2020 at an average price of €106.13.

DSM announces regular repurchase to cover share plans and stock dividend, in addition to ongoing repurchase to complete €1 billion share buy-back

DSM will repurchase 1,400,000 ordinary shares to cover share plans and stock dividend.

DSM publishes 2019 Integrated Annual Report

2019 Integrated Annual Report on DSM's performance and progress during 2019 in terms of People, Planet and Profit published.

DSM appoints new EVP Materials and member of the Executive Committee

Helen Mets appointed Executive Vice President Materials and member of the Executive Committee as of 1 March 2020.

DSM - repurchase of shares (17-21 February 2020)

DSM repurchased 183,602 shares from 17 to 21 February 2020 at an average price of €115.01.

DSM to acquire Glycom to accelerate growth in Early Life Nutrition

DSM to acquire world's leading supplier of Human Milk Oligosaccharides (HMO) for early life nutrition applications.

DSM - repurchase of shares (10-14 February 2020)

DSM repurchased 80,423 shares from 10 to 14 February 2020 at an average price of €116.31.

DSM reports 2019 results

DSM delivered a good financial performance for the year and achieved the key milestones in the first year of its Strategy 2021.

DSM - repurchase of shares (3-7 February 2020)

DSM repurchased 80,423 shares from 3 to 7 February 2020 at an average price of €113.07.

DSM - repurchase of shares (27-31 January 2020)

DSM repurchased 195,502 shares from 27 to 31 January 2020 at an average price of €110.38.

DSM - repurchase of shares (20-24 January 2020)

DSM repurchased 110,420 shares from 20 to 24 January 2020 at an average price of €111.85.

DSM partners with Generation Unlimited to create employment opportunities for young people in agri-food businesses

Partnership aims to create a longer-term vision for sustainable food systems in Africa.

DSM - repurchase of shares (13-17 January 2020)

DSM repurchased 213,886 shares from 13 to 17 January 2020 at an average price of €109.84.

DSM names Feike Sijbesma Honorary Chairman

As Honorary Chairman Feike Sijbesma will continue to act as DSM's ambassador.

DSM - repurchase of shares (6-10 January 2020)

DSM repurchased 225,888 shares from 6 to 10 January 2020 at an average price of €114.73.

DSM - repurchase of shares (2-3 January 2020)

DSM repurchased 28,011 shares from 2 to 3 January 2020 at an average price of €116.83.

Royal DSM completes acquisition of Royal CSK

DSM acquires specialty dairy solutions provider CSK (Koninklijke CSK Food Enrichment C.V.) for about €150 million.

DSM - repurchase of shares (16-20 December 2019)

DSM repurchased 308,286 shares from 16 to 20 December 2019 at an average price of €115.95.

DSM - repurchase of shares (9-13 December 2019)

DSM repurchased 347,955 shares from 9 to 13 December 2019 at an average price of €114.42.

DSM - repurchase of shares (2-6 December 2019)

DSM repurchased 438,649 shares from 2 to 6 December 2019 at an average price of €114.60.

Update on DSM Supervisory Board composition

Thomas Leysen nominated as new Supervisory Board member while Rob Routs, Eileen Kennedy & Pradeep Pant nominated for reappointment.

DSM - repurchase of shares (25-29 November 2019)

DSM repurchased 284,636 shares from 25 to 29 November 2019 at an average price of €117.00.

Royal DSM announces CEO succession

CEO Feike Sijbesma will hand over his responsibilities to Managing Board colleagues Geraldine Matchett and Dimitri de Vreeze as Co-CEO’s in February 2020.

DSM - repurchase of shares (18-22 November 2019)

DSM repurchased 445,046 shares from 18 to 22 November 2019 at an average price of €116.60.

DSM - repurchase of shares (11-15 November 2019)

DSM repurchased 428,180 shares from 11 to 15 November 2019 at an average price of €116.15.

Royal DSM to acquire Royal CSK, combining complementary strengths to better serve global dairy industries

Acquisition strengthens dairy portfolio and application know-how and expertise, particularly in the areas of cheese taste, texture and bio-preservation.

DSM - repurchase of shares (4-8 November 2019)

DSM repurchased 358,500 shares from 4 to 8 November 2019 at an average price of €114.17.

DSM - repurchase of shares (28 October - 1 November 2019)

DSM repurchased 196,255 shares from 28 October to 1 November 2019 at an average price of €107.26.

DSM reports results first nine months 2019

DSM reports a good first nine months in 2019 with a solid performance in Q3.

DSM - repurchase of shares (21-25 October 2019)

DSM repurchased 153,111 shares from 21 to 25 October 2019 at an average price of €106.73.

DSM - repurchase of shares (14-18 October 2019)

DSM repurchased 190,019 shares from 14 to 18 October 2019 at an average price of €108.44.

DSM - repurchase of shares (7-11 October 2019)

DSM repurchased 183,500 shares from 7 to 11 October 2019 at an average price of €107.03.

DSM - repurchase of shares (30 September - 4 October 2019)

DSM repurchased 212,170 shares from 30 September to 4 October 2019 at an average price of €107.78.

DSM - repurchase of shares (23-27 September 2019)

DSM repurchased 162,212 shares from 23 to 27 September 2019 at an average price of €106.77.

DSM - repurchase of shares (16-20 September 2019)

DSM repurchased 274,642 shares from 16 to 20 September 2019 at an average price of €108.43

DSM - repurchase of shares (9-13 September 2019)

DSM repurchased 245,676 shares from 9 to 13 September 2019 at an average price of €113.21.

DSM - repurchase of shares (2-6 September 2019)

DSM repurchased 131,289 shares from 2 to 6 September 2019 at an average price of €115.38.

DSM celebrates 150 years of biotechnology innovation

DSM celebrates 150 years of rich history in social entrepreneurship and biotechnology innovations in the Dutch city of Delft

DSM - repurchase of shares (26-30 August 2019)

DSM repurchased 95,745 shares from 26 to 30 August 2019 at an average price of €110.88.

DSM - repurchase of shares (19-23 August 2019)

DSM repurchased 168,100 shares from 19 to 23 August 2019 at an average price of €110.62.

DSM completes creation of vitamin E Joint Venture with Nenter and begins upgrade of plant

JV consists of vitamin E production facilities in Jingzhou and a minority shareholding in Nenter’s intermediates facility in Shishou, China.

DSM - repurchase of shares (12-16 August 2019)

DSM repurchased 276,022 shares from 12 to 16 August 2019 at an average price of €108.76.

DSM - repurchase of shares (5-9 August 2019)

DSM repurchased 263,977 shares from 5 to 9 August 2019 at an average price of €108.13.

DSM - repurchase of shares (29 July - 2 August 2019)

DSM repurchased 131,000 shares from 29 July to 2 August 2019 at an average price of €112.52.

DSM reports H1 2019 results

DSM reports a good H1 2019 and maintains the previously increased full year outlook.

DSM - repurchase of shares (8-12 July 2019)

DSM repurchased 19,871 shares from 8 to 12 July 2019 at an average price of €109.81.

DSM and Evonik take next step in sustainable aquaculture: Veramaris facility starts commercial production

Veramaris' commercial-scale $200 million facility for production of omega-3 EPA & DHA from natural marine algae opens in Nebraska (US).

DSM - repurchase of shares (1-5 July 2019)

DSM repurchased 41,213 shares from 1 to 5 July 2019 at an average price of €109.50.

DSM - repurchase of shares (24-28 June 2019)

DSM repurchased 150,213 shares from 24 to 28 June 2019 at an average price of €108.69.

DSM announces Kazunori Maruyama as President of DSM Japan

Kazunori Maruyama brings a wealth of experience and will continue to strengthen DSM's second largest business in Asia.

In Memoriam Simon de Bree

It is with great sadness that we share the news that our former Managing Board Chairman Simon de Bree has passed away.

DSM announces early redemption of the €300 million 1.75% bond maturing 13 November 2019

DSM exercises right to redeem all the €300,000,000 1.75% Notes due on 13 November on first optional redemption date of 13 August 2019.

DSM - repurchase of shares (17-21 June 2019)

DSM repurchased 94,194 shares from 17 to 21 June 2019 at an average price of €108.56.

DSM - repurchase of shares (10-14 June 2019)

DSM repurchased 147,395 shares from 10 to 14 June 2019 at an average price of €106.02.

DSM - repurchase of shares (3-7 June 2019)

DSM repurchased 206,267 shares from 3 to 7 June 2019 at an average price of €102.96.

DSM - repurchase of shares (27-31 May 2019)

DSM repurchased 163,903 shares from 27 to 31 May 2019 at an average price of €100.64.

DSM - repurchase of shares (20-24 May 2019)

DSM repurchased 284,500 shares from 20 to 24 May 2019 at an average price of €101.52.

DSM - repurchase of shares (13-17 May 2019)

DSM repurchased 222,500 shares from 13 to 17 May 2019 at an average price of €99.97.

DSM - repurchase of shares (6-10 May 2019)

DSM repurchased 494,782 shares from 6 to 10 May 2019 at an average price of €101.18.

DSM expands in India with acquisition of SRF Ltd.’s Specialty Materials business

DSM to acquire leading player in the development, production and sale of specialty materials in India.

Annual General Meeting of Shareholders 2019

Summary of the resolutions and voting at DSM's Annual General Meeting of Shareholders 2019.

Final dividend 2018 Royal DSM

DSM declares a dividend for the financial year 2018 of €2.30 per ordinary share.

DSM announces results of 2019 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 8 May 2019. Shareholders approved all resolutions on the agenda.

DSM - repurchase of shares (29 April - 3 May 2019)

DSM repurchased 172,159 shares from 29 April to 3 May 2019 at an average price of €100.61.

DSM reports Q1 2019 results

DSM reports a good start to the year and increases full year outlook.

DSM - repurchase of shares (23-26 April 2019)

DSM repurchased 165,141 shares from 23 to 26 April 2019 at an average price of €101.54.

DSM - repurchase of shares (15-18 April 2019)

DSM repurchased 123,006 shares from 15 to 18 April 2019 at an average price of €102.40.

DSM - repurchase of shares (8-12 April 2019)

DSM repurchased 229,636 shares from 8 to 12 April 2019 at an average price of €101.48.

DSM - repurchase of shares (1-5 April 2019)

DSM repurchased 144,066 shares from 1 to 5 April 2019 at an average price of €99.84.

DSM Executive Committee members purchase DSM shares

All seven members of the Executive Committee to purchase shares in Royal DSM by converting 50% of their gross STI's into ordinary shares.

DSM proposes new supervisory board member

Shareholders to vote on Erica Mann's appointment, and Pauline van der Meer Mohr's re-appointment, as members of DSM's Supervisory Board.

DSM completes increase shareholding in Andre Pectin to 75%

DSM increases shareholding in Andre Pectin, a leading specialty food ingredient producer of hydrocolloids to 75%.

DSM commences €1 billion share buy-back and announces regular repurchase to cover share plans and stock dividend

€1 billion buy back intended to reduce issued capital, plus a further repurchase of 2,600,000 shares to cover share plans and stock dividend.

DSM sets science-based reduction targets for emissions

DSM’s targets assessed by Science Based Targets initiative to be in line with the level of decarbonization required to keep global temperature increase below 2° C.

DSM’s 2018 Integrated Annual Report: strong progress on People, Planet and Profit, creating value for all stakeholders

Report demonstrates DSM’s consistent progress as a growth company with ambitious business and sustainability efforts that creates People, Planet and Profit value.

DSM announces start of Avansya

50/50 Joint Venture with Cargill will produce zero-calorie, great-tasting sweeteners through fermentation.

DSM reports 2018 results

DSM reports a very strong year, including a robust Q4 and increases dividend by 25% from €1.85 to €2.30 per ordinary share.

DSM celebrates 30 years as a listed company

At the time DSM's IPO was the biggest introduction in the history of the Amsterdam Stock Exchange.

DSM announces agreement to increase its shareholding in Andre Pectin from 29% to 75%

DSM will increase its shareholding in Yantai Andre Pectin Co. Ltd. (Andre Pectin), a leading specialty food ingredient producer of hydrocolloids.

DSM announces management change DSM Netherlands

Edith Schippers, who was most recently Minister of Health, Welfare and Sports in the Netherlands who will join DSM on 1st February, replacing Atzo Nicolaï.

DSM announces new Chief Innovation Officer

Patricia Malarkey, most recently Head of Research & Development and member of the Executive Committee at Syngenta, will join DSM as Chief Innovation Officer and member of the Executive Committee.

DSM announces JV with Nenter to produce vitamin E

DSM will create a 75/25 joint venture with Nenter & Co., Inc., which will include all Nenter’s production and related assets for Vitamin E.

DSM pioneers a biogum future

DSM Hydrocolloids strengthens foothold in the industry and unveils new brand identities for its gellan gum and xanthan gum portfolios.

DSM North America opens newly expanded 66 acre solar field in Belvidere, New Jersey

20.2 MW solar project now largest net-metered solar installation in New Jersey and the second largest on the US East Coast.

DSM reports 2017 results

DSM again reports an excellent year, as it significantly exceeded its Strategy 2018 targets for EBITDA, ROCE and organic sales growth.

DSM publishes 2017 Integrated Annual Report

The 2017 Integrated Annual Report details the company's progress and performance over the year in terms of People, Planet and Profit.

DSM announces repurchase of shares to cover share based compensation plans and stock dividend

DSM intends to repurchase 1,600,000 ordinary shares to cover commitments under share based compensation plans and and part of the final dividend 2017.

DSM - repurchase of shares (19-22 March 2018)

DSM repurchased 136,650 shares from 19 to 22 March 2018 at an average price of €80.59.

DSM - repurchase of shares (23-29 March 2018)

DSM repurchased 188,000 shares from 23 to 29 March 2018 at an average price of €79.38.

DSM - repurchase of shares (3-5 April 2018)

DSM repurchased 87,000 shares from 3 to 5 April 2018 at an average price of €80.10.

DSM announces preliminary Q1 2018 results and increases outlook

Continued strong organic sales growth in underlying business estimated at 11%. Adjusted EBITDA growth of underlying business estimated at 7% despite significant FX headwind. Additional temporary vitamin price benefit estimated at €165m on Adjusted EBITDA. Overall very strong quarter with total Adjusted EBITDA up 55%.

DSM - repurchase of shares (6-12 April 2018)

DSM repurchased 88,350 shares from 6 to 12 April 2018 at an average price of €81.74.

DSM reports Q1 2018 results

Royal DSM issues its full Q1 2018 results, which are in line with the preliminary figures for Q1 2018 previously announced on 12 April 2018.

DSM announces results of 2018 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 9 May 2018. Shareholders approved all resolutions on the agenda.

Final dividend 2017 Royal DSM

DSM declares a dividend for the financial year 2017 of €1.85 per ordinary share.

DSM informs market on the announced sale of Fibrant’s Caprolactam business to Highsun

DSM and CVC Capital Partners indirectly own 35% and 65% respectively of the shares of Fibrant BV through Chemicalnvest joint venture.

DSM - repurchase of shares (14-17 May 2018)

DSM repurchased 91,500 shares from 14 to 17 May 2018 at an average price of €87.39.

DSM - repurchase of shares (18-24 May 2018)

DSM repurchased 176,500 shares from 18 to 24 May 2018 at an average price of €88.02.

DSM links Greenhouse Gas emission reduction to interest rate in new €1 billion Revolving Credit Facility

DSM has linked the interest rate of new €1 billion Revolving Credit Facility to its performance on the reduction of GHG emissions.

DSM - repurchase of shares (25-31 May 2018)

DSM repurchased 233,975 shares from 25 to 31 May 2018 at an average price of €86.30.

DSM - repurchase of shares (1-7 June 2018)

DSM repurchased 141,033 shares from 1 to 7 June 2018 at an average price of €88.22.

DSM - repurchase of shares (8-14 June 2018)

DSM repurchased 132,098 shares from 8 to 14 June 2018 at an average price of €89.07.

DSM strategy update

With its unique science-based competences, DSM is ideally positioned to capture the growth opportunities offered by the global megatrends and Sustainable Development Goals (SDGs), with a particular focus on Nutrition & Health, Climate & Energy and Resources & Circularity.

DSM finalizes repurchase of shares to cover existing option plans and stock dividends

DSM repurchased 324,894 shares from 15 to 20 June 2018 at an average price of €88.18, concluding program to repurchase 1,600,000 shares for a total of €136.7 million.

AkzoNobel Specialty Chemicals, DSM, Google and Philips receive first power from new Dutch windfarm Bouwdokken

Companies signed two long-term power purchase agreements (PPAs) that enabled construction of two windfarm projects.

Redirect to Honorary Chairman PR

Redirect to Honorary Chairman PR

Africa Improved Foods celebrates one year

AIF’s plant in Kigali has an annual production capacity of 45,000 tons making it one of the largest nutrition factory sites on the continent and it works with over 9,000 farmers across Rwanda and produces meals for 1.5 million people every day.

DSM operates on 100% renewable purchased electricity in the Netherlands

From 2018 all DSM's purchased electricity in the Netherlands will come from renewable sources, thanks to an agreement with Dutch energy supplier Eneco.

DSM and WFP extend their partnership to tackle malnutrition

DSM has extended its partnership with the World Food Programme by 3 years to continue fighting hidden hunger and enabling better nutrition for vulnerable people.

Supporting climate adaptation

Improving society’s ability to adapt to a changing climate.

DSM informs market on the announced sale of DSM Sinochem Pharmaceuticals to Bain Capital

Bain Capital intends to acquire DSM Sinochem Pharmaceuticals, a DSM and Sinochem Group 50/50 joint venture, with the transaction expected to be completed in the fourth quarter of 2018 subject to customary regulatory approvals and consultations.

DSM becomes largest shareholder in Mixfit Inc. to enter B2C personalized nutrition

Acquisition builds on partnership combining DSM’s unparalleled expertise in micronutrients with Mixfit technology.

DSM reports H1 2018 results

DSM reports a very good H1 with strong performance across all businesses.

DSM announces repurchase of shares to cover share-based compensation plans and stock dividend

DSM intends to repurchase 1,100,000 ordinary shares: 500,000 to cover commitments under share-based compensation plans and 600,000 to cover part of the interim dividend 2018.

DSM - repurchase of shares (13-17 August 2018)

DSM repurchased 215,656 shares from 13 to 17 August 2018 at an average price of €89.80.

DSM ranked by Fortune Magazine’s ‘Change the World’ list and Sustainalytics

DSM named on Fortune Magazine’s ‘Change the World’ List for third consecutive year and again ranked number 1 globally in sustainability by Sustainalytics

DSM - repurchase of shares (20-24 August 2018)

DSM repurchased 82,975 shares from 20 to 24 August 2018 at an average price of €89.58.

DSM - repurchase of shares (27-31 August 2018)

DSM repurchased 117,471 shares from 27 to 31 August 2018 at an average price of €91.17.

DSM - repurchase of shares (3-7 September 2018)

DSM repurchased 189,309 shares from 3 to 7 September 2018 at an average price of €88.16.

DSM tops Dow Jones Sustainability World Index

DSM recognized among the DJSI leaders for 15 years running and held the number one position in the sector eight times.

DSM - repurchase of shares (10-14 September 2018)

DSM repurchased 94,032 shares from 10 to 14 September 2018 at an average price of €88.38.

DSM - repurchase of shares (17-21 September 2018)

DSM repurchased 69,638 shares from 17 to 21 September 2018 at an average price of €91.24.

DSM - repurchase of shares (24-28 September 2018)

DSM repurchased 121,592 shares from 24 to 28 September 2018 at an average price of €91.88.

DSM finalizes repurchase of shares to cover existing option plans and stock dividends

DSM repurchased 209,327 shares from 1 to 5 October 2018 at an average price of €90.13, finalizing program to repurchase 1,100,000 shares for a total of €98.9 million.

DSM welcomes new Sustainability Advisory Board member Ertharin Cousin

Ertharin Cousin, former Executive Director of the United Nations World Food Programme, has joined DSM's Sustainability Advisory Board.

DSM informs market on the completion of the sale of Fibrant’s caprolactam business to Highsun

DSM anticipates receiving about €200 million in cash in various steps in 2018 and 2019.

DSM reports results first nine months 2018

DSM reports another very good quarter and is confident in achieving full year outlook.

DSM informs market on the completion of the sale of DSM Sinochem Pharmaceuticals to Bain Capital

Bain Capital completes acquisition of DSM Sinochem Pharmaceuticals from DSM and Sinochem, both of whom held an equity stake of 50%.

Cargill and Royal DSM to establish joint venture to bring zero-calorie, cost-effective sweeteners to market faster

Companies to produce highly sought-after molecules such as steviol glycosides Reb M and Reb D through fermentation.

Annual General Meeting of Shareholders 2018

Summary of the resolutions and voting at DSM's Annual General Meeting of Shareholders 2018.

DSM and Amyris close transactions for Brazilian production facility

Sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’s high-volume products finalized.

DSM acquires BioCare Copenhagen to expand gut health ingredients portfolio with probiotics

DSM expands its offering in gut health ingredients with probiotics, an attractive market segment in nutritional ingredients, growing an estimated 7% per year.

DSM calls for accelerated climate action as part of a broad coalition of major global companies

Call for framework conditions laying foundation for a pathway to limiting global temperature rise to well below 2° Celsius and allow them to actively contribute to the implementation of the Paris Agreement.

RMI case study showcases successful aggregation of corporate renewable energy demand

Report details how four major corporate renewable energy buyers came together to successfully aggregate demand and jointly sign multiple wind power PPAs in Europe.

DSM expands strategic alliance with Amyris and acquires Brazilian production facility from Amyris

DSM and Amyris enhance their strategic alliance through the sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’ high-volume products.

DSM finalizes repurchase of shares to cover existing option plans and stock dividends

DSM repurchased 151,900 shares from 10 to 14 November 2017 at an average price of €75.63, concluding program to repurchase 1,600,000 shares for a total of €109.3 million.

DSM to operate on 40% renewable electricity in the U.S. thanks to new wind power agreement with NextEra

DSM positioned to outpace its global target of 50% purchased electricity from renewable sources by 2025.

DSM and Haixing strengthen hydrocolloids business with acquisition of Inner Mongolia Rainbow Biotechnology Co., Ltd. (China)

DSM and Haixing will be able to expand their global business of sustainable and innovative hydrocolloid solutions applied in food, beverage and personal care products to provide texture and stability.

DSM - repurchase of shares (3-9 November 2017)

DSM repurchased 243,624 shares from 3 to 9 November 2017 at an average price of €76.15.

DSM reports results first nine months 2017

Strong performance in Q3 2017, contributing to very good first nine months.

DSM, UNICEF, and Sight and Life partner to deliver better nutrition in Nigeria

Partnership to focus on reaching mothers and children with nutrition interventions during the crucial first 1,000 days of children’s lives, from conception to age 2.

Redirect to Honorary Chairman PR

DSM - repurchase of shares (6-12 October 2017)

DSM repurchased 37,600 shares from 6 to 12 October 2017 at an average price of €69.54.

DSM - repurchase of shares (29 September - 5 October 2017)

DSM repurchased 140,692 shares from 29 September to 5 October 2017 at an average price of €69.52.

DSM reports fatal accident at Augusta site

On 27 September 2017 a fatal accident took place at DSM's site in Augusta (GA, US), in which a contractor sadly lost his life and two others injured, and expected to recover.

DSM - repurchase of shares (22-28 September 2017)

DSM repurchased 163,310 shares from 22 to 28 September 2017 at an average price of €67.75.

DSM updates market on Strategy 2018

EBITDA and ROCE outlook for 2017 confirmed. DSM aims to continue to deliver against its strategic targets in 2018. DSM brings forward its regular strategic review process for the period beyond 2018 and expects to share the conclusions before the summer of 2018.

DSM - repurchase of shares (15-21 September 2017)

DSM repurchased 117,424 shares from 15 to 21 September 2017 at an average price of €66.56.

DSM to acquire Twilmij B.V. to strengthen position in Animal Nutrition & Health

Twilmij’s core values, customer portfolio and solutions are a perfect fit with DSM’s ambitions in the animal nutrition & health market.

DSM - repurchase of shares (8-14 September 2017)

DSM repurchased 128,851 shares from 8 to 14 September 2017 at an average price of €66.04.

DSM 2nd on Fortune’s “Change the World” list

DSM in 2nd place in Fortune Magazine’s 3rd annual Change the World list, which recognizes 56 companies that have had a positive social impact through activities that are part of their core business strategy.

DSM - repurchase of shares (1-7 September 2017)

DSM repurchased 142,315 shares from 1 to 7 September 2017 at an average price of €65.01.

DSM among leaders in Dow Jones Sustainability World Index

DSM again named among worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index having been named among the global leaders for the past 14 years and holding the number one position in the sector seven times, including last year.

DSM - repurchase of shares (25-31 August 2017)

DSM repurchased 188,430 shares from 25 to 31 August 2017 at an average price of €64.01.

In Memoriam Peter Elverding

It is with great sadness that we share the news that our friend and former colleague, Peter Elverding has passed away.

DSM informs market on Patheon N.V.

Thermo Fisher Scientific Inc. has completed the acquisition of Patheon N.V. (NYSE:PTHN), a company in which DSM held approximately 48.7 million ordinary shares.

DSM - repurchase of shares (18-24 August 2017)

DSM repurchased 185,837 shares from 18 to 24 August 2017 at an average price of €63.98.

DSM - repurchase of shares (14-17 August 2017)

DSM repurchased 100,017 shares from 14 to 17 August 2017 at an average price of €63.21.

DSM announces repurchase of shares to cover existing option plans and stock dividend

DSM intends to repurchase 1,600,000 ordinary shares to cover commitments under management and personnel option plans and for part of the interim dividend 2017.

DSM reports H1 2017 results

DSM maintained its positive momentum with a very strong first half-year performance with Q2 another very good quarter.

DSM appoints new EVP People & Organization and member of the Executive Committee

Judith Wiese will join DSM as Executive Vice President Group People & Organization on 1 October 2017.

DSM finalizes repurchase of shares to cover existing option plans and stock dividends

DSM repurchased 261,898 shares from 7 to 13 July 2017 at an average price of €63.24, concluding program to repurchase 2,900,000 shares for a total of €187.2 million.

DSM - repurchase of shares (30 June - 6 July 2017)

DSM repurchased 218,403 shares from 30 June to 6 July 2017 at an average price of €63.72.

DSM - repurchase of shares (23-29 June 2017)

DSM repurchased 182,175 shares from 23 to 29 June 2017 at an average price of €65.07.

DSM - repurchase of shares (16-22 June 2017)

DSM repurchased 122,307 shares from 16 to 22 June 2017 at an average price of €67.16.

DSM - repurchase of shares (9-15 June 2017)

DSM repurchased 123,435 shares from 9 to 15 June 2017 at an average price of €66.00.

Bright Minds Challenge award for Ernesto Julio Calvo with Inquimae

Support from DSM and global partners to scale-up 100% renewable energy solution.

DSM - repurchase of shares (2-8 June 2017)

DSM repurchased 132,717 shares from 2 to 8 June 2017 at an average price of €65.73.

DSM - repurchase of shares (26 May - 1 June 2017)

DSM repurchased 123,673 shares from 26 May to 1 June 2017 at an average price of €66.16.

Key international partners to attend official Africa Improved Foods plant unveiling

AIF Rwanda now producing highly nutritious porridge flours (with added milk, vitamins and minerals) targeting vulnerable population segments such as pregnant and breast-feeding mothers, older infants and young children in the first 1,000 days of their lives.

DSM - repurchase of shares (19-25 May 2017)

DSM repurchased 123,847 shares from 19 to 25 May 2017 at an average price of €66.10.

DSM - repurchase of shares (12-18 May 2017)

DSM repurchased 139,447 shares from 12 to 18 May 2017 at an average price of €66.66.

DSM informs market on Patheon N.V.

Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per ordinary share in cash.

DSM - repurchase of shares (5-11 May 2017)

DSM repurchased 128,958 shares from 5 to 11 May 2017 at an average price of €65.76.

Royal DSM to make equity investment in Amyris with the purpose of establishing a long-term relationship

DSM to make equity investment in Amyris and the companies to enter development cooperation focused on products for the health and nutrition markets.

DSM - repurchase of shares (28 April - 4 May 2017)

DSM repurchased 114,048 shares from 28 April to 4 May 2017 at an average price of €66.44.

Final dividend 2016 Royal DSM

DSM declares a dividend for the financial year 2016 of €1.75 per ordinary share.

DSM announces results of 2017 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 3 May 2017. Shareholders approved all resolutions on the agenda.

Annual General Meeting of Shareholders 2017

Summary of the resolutions at DSM'S Annual General Meeting of Shareholders 2017.

DSM reports Q1 2017 results

DSM reports a very strong first quarter in 2017.

DSM - repurchase of shares (21-27 April 2017)

DSM repurchased 126,540 shares from 21 to 27 April 2017 at an average price of €65.81.

Redirect to Honorary Chairman PR

DSM - repurchase of shares (18-20 April 2017)

DSM repurchased 75,948 shares from 18 to 20 April 2017 at an average price of €65.02.

DSM - repurchase of shares (7-13 April 2017)

DSM repurchased 126,073 shares from 7 to 13 April 2017 at an average price of €65.16.

Bright Minds Challenge names three finalists in global solar energy and storage competition

Finalists selected from ten best science and entrepreneurial team submissions.

DSM - repurchase of shares (31 March - 6 April 2017)

DSM repurchased 134,338 shares from 31 March to 6 April 2017 at an average price of €64.04.

DSM opens new biotechnology center in Delft, the Netherlands

New state-of-the-art biotechnology facility will accelerate DSM’s biotechnology research and development capabilities for applications in food and nutrition, feed, fuel, pharma and bio-based materials.

DSM - repurchase of shares (24-30 March 2017)

DSM repurchased 235,605 shares from 24 to 30 March 2017 at an average price of €62.81.

DSM - repurchase of shares (17-23 March 2017)

DSM repurchased 308,025 shares from 17 to 23 March 2017 at an average price of €62.12.

DSM proposes Managing Board re-appointment and two new Supervisory Board members

DSM proposes re-appointment of Dimitri de Vreeze the Managing Board and appointment of John Ramsay and Frits van Paasschen to the Supervisory Board.

DSM - repurchase of shares (13-16 March 2017)

DSM repurchased 222,563 shares from 13 to 16 March 2017 at an average price of €62.92 for a total of €14.0 million.

DSM announces repurchase of shares to cover existing option plans and stock dividend

DSM to repurchase 2,900,000 ordinary shares to cover commitments under management and personnel option plans and for part of final dividend 2016.

DSM publishes 2016 Integrated Annual Report

2016 Integrated Annual Report, in which DSM reports on its progress and performance over the year in terms of People, Planet and Profit, published on 3 March 2017.

POET-DSM plans on-site enzyme manufacturing facility at Project Liberty

Plant has achieved 70 gallon per ton conversion rate and POET-DSM Advanced Biofuels will now build an on-site enzyme manufacturing facility in Emmetsburg, Iowa, pending state and local approvals.

DSM reports 2016 results

DSM reports a very good 2016 in which it achieved strong EBITDA and ROCE growth, well ahead of the mid-term targets set out in its Strategy 2018: Driving Profitable Growth.

DSM new presentation of accounts as from Q4 2016

DSM updates way its financial results are presented starting with Q4/full-year results for 2016, following recent changes to accounting and reporting guidelines in Europe.

DSM welcomes new Sustainability Advisory Board member Robin Chase

Robin Chase, cofounder and former CEO of Zipcar, member of Boards of Veniam, World Resources Institute and Tucows and advisor to French National Digital Agency and USDOT’s Advisory Committee on Automated Transportation, joins DSM's Sustainability Advisory Board.

DSM finalizes repurchase of shares to cover existing option plans

DSM repurchased 361,907 shares from 2 to 8 December 2016 at an average price of €56.21 and concluded the program to repurchase 1,700,000 shares.

DSM - repurchase of shares (25 November 2016 - 1 December 2016)

DSM repurchased 215,424 of its own shares from 25 November to 1 December 2016 at an average price of €57.32.

DSM - repurchase of shares (18-24 November 2016)

DSM repurchased 248,036 shares from 18 to 24 November 2016 at an average price of €57.14.

DSM Managing Board change

DSM announces the departure of Managing Board and Executive Committee member Stephan B. Tanda as of 1 February 2017.

DSM - repurchase of shares (11-17 November 2016)

DSM repurchased 360,149 shares from 11 to 17 November 2016 at an average price of €56.21.

DSM reports Q3 2016 results

DSM reports another strong quarter in Q3 2016.

DSM - repurchase of shares (4-10 November 2016)

DSM repurchased 514,484 shares from 4 to 10 November 2016 at an average price of €56.17.

DSM announces repurchase of shares to cover existing option plans

DSM intends to repurchase up to 1,700,000 ordinary shares in order to cover its commitments under management and personnel option plans.

DSM issues long-term €750 million bond

DSM announces the successful launch of a €750 million bond, with a ten-year maturity due in 2026, at a coupon of 0.75%.

DSM named leader in Dow Jones Sustainability World Index

DSM has been named the worldwide leader in the Materials industry group in the Dow Jones Sustainability World Index 2016.

DSM reports Q2 2016 results

DSM reports a second consecutive strong quarter in 2016.

DSM successfully completes secondary offering of shares in Patheon N.V.

DSM announces the successful completion of its secondary offering of 4,761,905 ordinary shares in Patheon N.V. in connection with Patheon N.V.’s Initial Public Offering of ordinary shares.

DSM finalizes repurchase of shares to cover existing option plans and stock dividend

DSM repurchased 83,073 shares from 15 to 21 July 2016 at an average price of €56.75 and concluded the program to repurchase 3,500,000 shares.

DSM informs market of final pricing of Patheon N.V. IPO

Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has priced its Initial Public Offering at USD 21.00 per ordinary share.

DSM - repurchase of shares (8-14 July 2016)

DSM repurchased 107,432 shares from 8 to 14 July 2016 at an average price of €54.67.

DSM informs market of amended S-1 filing by Patheon N.V.

Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has today commenced an Initial Public Offering.

DSM - repurchase of shares (1-7 July 2016)

DSM repurchased 95,055 shares from 1 to 7 July 2016 at an average price of €52.09.

DSM - repurchase of shares (24-30 June 2016)

DSM repurchased 248,553 shares from 24 to 30 June 2016 at an average price of €50.64.

Increased crash protection with Dyneema®

Protective properties of the bib-shorts are further enhanced by a new and optimized design of the Dyneema fabric.

DSM - repurchase of shares (17-23 June 2016)

DSM repurchased 115,202 shares from 17 to 23 June 2016 at an average price of €53.57.

DSM - repurchase of shares (10-16 June 2016)

DSM repurchased 125,684 shares from 10 to 16 June 2016 at an average price of €53.20.

DSM announces amendment to share repurchase program and reports repurchase of shares (3-9 June 2016)

DSM intends to increase the running share repurchase program by an additional 300,000 shares to a total of 3,500,000 to cover the interim stock dividend 2016.

DSM - repurchase of shares (27 May 2016 - 2 June 2016)

DSM repurchased 151,361 shares from 27 May to 2 June 2016 at an average price of €54.46.

DSM - repurchase of shares (20-26 May 2016)

DSM repurchased 152,420 shares from 20 to 26 May 2016 at an average price of €53.26

DSM - repurchase of shares (13-19 May 2016)

DSM repurchased 152,511 shares from 13 to 19 May 2016 at an average price of €52.54.

DSM - repurchase of shares (6-12 May 2016)

DSM repurchased 153,360 shares from 6 to 12 May 2016 at an average price of €52.27.

DSM - repurchase of shares (29 April - 5 May 2016)

DSM repurchased 153,694 shares from 29 April to 5 May 2016 at an average price of €52.34.

DSM provides update on Nutrition organization to support growth

DSM provides an update on the development of its Nutrition organization and several key positions to further support its growth plans.

DSM announces results of 2016 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 29 April 2016. Shareholders approved all resolutions on the agenda.

Annual General Meeting of Shareholders 2016

Summary of the resolutions at DSM'S Annual General Meeting of Shareholders 2016.

DSM - repurchase of shares (22-28 April 2016)

DSM repurchased 163,523 shares from 22 to 28 April 2016 at an average price of €53.25.

Final dividend 2015 Royal DSM

DSM declares a dividend for the financial year 2015 of €1.65 per ordinary share of €1.50 nominal value.

DSM reports Q1 2016 results

DSM reports a strong first quarter in 2016.

DSM - repurchase of shares (15-21 April 2016)

DSM repurchased 153,579 shares from 15 to 21 April 2016 at an average price of €52.05.

DSM - repurchase of shares (8-14 April 2016)

DSM repurchased 153,992 shares from 8 to 14 April 2016 at an average price of €50.01.

DSM - repurchase of shares (1-7 April 2016)

DSM repurchased 167,229 shares from 1 to 7 April 2016 at an average price of €47.8951.

DSM - repurchase of shares (29-31 March 2016)

DSM repurchased 93,033 shares from 29 to 31 March 2016 at an average price of €48.5712.

DSM Executive Committee members purchase DSM shares

All members of the Executive Committee purchase ordinary shares in Royal DSM, expressing their confidence in the growth prospects of the company.

DSM - repurchase of shares (18-24 March 2016)

DSM repurchased 159,637 shares from 18 to 24 March 2016 at an average price of €48.28.

DSM - repurchase of shares (11-17 March 2016)

DSM repurchased 161,667 shares from 11 to 17 March 2016 at an average price of €48.06.

DSM - repurchase of shares (4-10 March 2016)

DSM repurchased 232,331 shares from 4 to 10 March 2016 at an average price of €47.13.

DSM - repurchase of shares (26 February 2016 - 3 March 2016)

DSM repurchased 269,930 shares from 26 February to 3 March 2016 at an average price of €45.84.

DSM publishes 2015 Integrated Annual Report

DSM announces the publication of its 2015 Integrated Annual Report.

DSM - repurchase of shares (22-25 February 2016)

DSM repurchased 267,680 shares from 22 to 25 February 2016 at an average price of €43.94.

DSM welcomes new Sustainability Advisory Board member Ndidi Okonkwo Nwuneli

Ndidi Okonkwo Nwuneli, founder of LEAP Africa and co-founder of AACE Food Processing & Distribution Ltd and partner at Sahel Capital, an advisory and private equity firm, has joined DSM's Sustainability Advisory Board.

DSM announces repurchase of shares to cover existing option plans and stock dividend

DSM to repurchase 3,200,000 ordinary shares to cover commitments under management and personnel option plans and as part of the final dividend 2015.

DSM reports Q4 2015 results

Q4 Group net sales up 6% to €1,926m and EBITDA up 3% to €261m.

DSM proposes Pradeep Pant as new Supervisory Board member

At the Annual General Meeting of Shareholders the Supervisory Board will nominate Mr. Pradeep Pant for appointment as a member of DSM's Supervisory Board.

DSM and WFP reconfirm partnership to combat global malnutrition

DSM and the United Nations World Food Programme sign agreement extending their existing partnership to combat hidden hunger and malnutrition in the developing world to 2018.

DSM and Syngenta to develop and commercialize biological solutions for agriculture

DSM and Syngenta R&D partnership to develop microbial-based agricultural solutions, including bio-controls, bio-pesticides and bio-stimulants.

DSM sets Strategy 2018

After a period of transformation, DSM will focus on improving its financial results through organic growth, reducing costs and strict capital allocation.

DSM reports Q3 2015 results

Sales up 8%, driven by 7% organic growth in Nutrition and foreign exchange.

DSM wins FD-Sijthoff prize for best annual report by a Dutch listed company

DSM awarded FD-Henri Sijthoff prize for the best annual report by a company listed on the AEX stock exchange in the Netherlands for its 2014 Integrated Annual Report.

DSM issues long-term €500 million bond

DSM successfully issued a €500 million 1.375% bond due 2022.

DSM among leaders in Dow Jones Sustainability World Index

DSM named among the worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index 2015.

Dyneema® reinforced shorts win award

Eurobike Award is a fantastic recognition of a breakthrough development that greatly benefits professional and amateur riders alike.

DSM adjusts organizational model

Adjustments to organizational and operating model aim to create more agile, focused and cost efficient organization, with a stronger business and market focus and globally leveraged support functions.

DSM reports Q2 2015 results

Solid sales performance with a 12% increase to €1,965 million, supported by foreign exchange rates and 3% volume growth.

DSM and CVC finalize partnership for Polymer Intermediates and Composite Resins

Partnership finalized for DSM’s activities in Polymer Intermediates (Caprolactam & Acrylonitrile) and Composite Resins with formation of ChemicaInvest B.V..

DSM finalizes repurchase of shares to cover existing option plans

DSM repurchased 204,254 shares from 24 to 28 July 2015 at an average price of €52.44 and concluded the program to repurchase 2,300,000 shares.

DSM - repurchase of shares (17-23 July 2015)

DSM repurchased 184,648 shares from 17 to 23 July 2015 at an average price of €54.52.

DSM - repurchase of shares (10-16 July 2015)

DSM repurchased 74,088 shares from 10 to 16 July 2015 at an average price of €53.54.

DSM - repurchase of shares (3-9 July 2015)

DSM repurchased 190,870 shares from 3 to 9 July 2015 at an average price of €51.34.

DSM - repurchase of shares (26 June - 2 July 2015)

DSM repurchased 362,143 shares from 26 June to 2 July 2015 at an average price of €53.03.

Dyneema® powers riders’ shorts in Tour de France 2015

Shorts feature new fabric with Dyneema® fiber to provide increased protection to the thigh in the event of a crash.

DSM - repurchase of shares (19-25 June 2015)

DSM repurchased 245,123 shares from 19 to 25 June 2015 at an average price of €53.87.

DSM launches campaign to pay tribute to “caring” scientists

DSM begins debate on the contribution of science to society: www.sciencecanchangetheworld.org.

DSM - repurchase of shares (12-18 June 2015)

DSM repurchased 223,561 shares from 12 to 18 June 2015 at an average price of €52.87.

DSM - repurchase of shares (5-11 June 2015)

DSM repurchased 185,315 shares from 5 to 11 June 2015 at an average price of €53.36.

DSM - repurchase of shares (29 May - 4 June 2015)

DSM repurchased 277,686 shares from 29 May to 4 June 2015 at an average price of €53.95.

DSM - repurchase of shares (22-28 May 2015)

DSM repurchased 128,219 shares from 22 to 28 May 2015 at an average price of €53.8102.

DSM - repurchase of shares (18-21 May 2015)

DSM repurchased 224,093 shares from 18 to 21 May 2015 at an average price of €53.18.

DSM announces repurchase of shares to cover existing option plans

DSM intends repurchasing 2,300,000 ordinary shares in order to cover its commitments under management and personnel option plans.

Final dividend 2014 Royal DSM

DSM declares dividend for the financial year 2014 of €1.65 per ordinary share.

DSM announces results of 2015 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 30 April 2015. Shareholders approved all resolutions on the agenda.

Annual General Meeting of Shareholders 2015

Summary of the resolutions at DSM'S Annual General Meeting of Shareholders 2015.

DSM reports Q1 2015 results

Sales of €1,886 million, up 11%, including 2% organic sales growth.

DSM finalizes sale of DSM Synres to Standard Investment

DSM Synres produced solvent-borne alkyd and acrylic coating resins for the global coatings, adhesives and graphic arts markets.

DSM provides 2014 comparative figures

Figures reflect reclassification of Polymer Intermediates cluster and DSM Composite Resins to discontinued operations. Corporate Activities are restated and also reflect the sale of DSM Synres.

DSM issues long-term €500 million bond

DSM has successfully issued a €500 million 1.0% bond due 2025.

DSM finalizes acquisition of Aland (China)

DSM finalizes acquisition of Aland, a Hong Kong-based company producing vitamin C in mainland China.

DSM Managing Board re-appointments

DSM proposes re-appointment of Stephan B. Tanda and announces departure of Stefan Doboczky as of 1 June 2015.

DSM and CVC announce partnership for Polymer Intermediates and Composite Resins

Partnership for DSM’s activities in Polymer Intermediates (Caprolactam and Acrylonitrile) and Composite Resins with formation of new company 65% owned by CVC and 35% by DSM.

DSM finalizes sale of Euroresins to Cathay Investments

Euroresins, a distributor of products to the composite resins industry, sold to Cathay Investments.

DSM publishes 2014 Integrated Annual Report

DSM announces publication of 2014 Integrated Annual Report.

DSM reports 2014 results

Sales of €9,181 million, a 4% increase versus 2013. In line with market expectations, DSM reported EBITDA of €1,168 million compared to €1,261 million in 2013.

New innovation partnership in pro-cycling

Partnership aimed at enabling Team Giant-Alpecin to benefit from DSM's innovative power.

DSM to sell Euroresins to Cathay Investments

DSM has reached agreement with Cathay Investments for the sale of Euroresins and the transaction is expected to close in Q1 2015.

DSM to sell DSM Synres to Standard Investment

DSM has reached agreement with Standard Investment for the sale of DSM Synres and the transaction is expected to close in Q1 2015.

DSM updates financial markets at its Capital Markets Day

DSM provides investors with update on its strategic progress and current priorities at annual Capital Markets Day.

DSM reports Q3 2014 results

Third quarter 2014 EBITDA from continuing operations of €315 million compared to €293 million in Q2 2014 and €331 million in Q3 2013.

DSM once again among leaders in DJ Sustainability World Index

DSM named among the worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index 2014.

First commercial-scale cellulosic ethanol plant in the U.S. opens for business

POET-DSM Advanced Biofuels proves its revolutionary technology that converts agricultural residue into renewable fuel at opening of its first commercial cellulosic ethanol plant.

DSM reports Q2 2014 results

DSM's second quarter 2014 EBITDA from continuing operations of €293 million compared to €332 million in Q2 2013, and €272 million in Q1 2014.

DSM to acquire Aland (China) to strengthen vitamin C position

DSM reaches agreement to acquire Aland, a Hong Kong-based company producing vitamin C in mainland China.

DSM reports fire in utilities building in Sisseln (CH)

Production of a few intermediates, mainly for Animal Nutrition & Health interrupted. Impact on customers expected to be minimal.

DSM finalizes repurchase of shares to cover existing option plans

DSM repurchased 69,522 shares from 16 to 19 May 2014 at an average price of €51.67 and concluded the program to repurchase 5,000,000 shares.

DSM - repurchase of shares (9-15 May 2014)

DSM repurchased 176,832 shares from 9 to 15 May 2014 at an average price of €51.97.

DSM - repurchase of shares (2-8 May 2014)

DSM repurchased 294,921 shares from 2 to 8 May 2014 at an average price of €52.03.

Final dividend 2013 Royal DSM

DSM declares dividend for the financial year 2013 of €1.65 per ordinary share.

DSM announces results of 2014 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 7 May 2014. Shareholders approved all resolutions on the agenda.

Annual General Meeting of Shareholders 2014

Summary of the resolutions at DSM'S Annual General Meeting of Shareholders 2014.

DSM reports Q1 2014 results

DSM reports first quarter EBITDA from continuing operations of €272 million compared to €301 million in Q1 2013.

DSM - repurchase of shares (25-30 April 2014)

DSM repurchased 201,426 shares from 25 to 30 April 2014 at an average price of €51.49.

DSM - repurchase of shares (22-24 April 2014)

DSM repurchased 170,120 shares from 22 to 24 April 2014 at an average price of €50.42.

DSM - repurchase of shares (11-17 April 2014)

DSM repurchased 231,586 shares from 11 to 17 April 2014 at an average price of €49.15.

DSM - repurchase of shares (4-10 April 2014)

DSM repurchased 256,801 shares from 4 to 10 April 2014 at an average price of €50.17.

DSM in exclusive discussions to acquire Aland (China)

DSM in exclusive discussions with Aland that may or may not result in the acquisition of this China-based global producer of vitamin C.

DSM - repurchase of shares (28 March - 3 April 2014)

DSM repurchased 149,321 shares from 28 March to 3 April 2014 at an average price of €50.05.

DSM - repurchase of shares (21-27 March 2014)

DSM repurchased 157,579 shares from 21 to 27 March 2014 at an average price of €48.46.

DSM - repurchase of shares (14-20 March 2014)

DSM repurchased 108,500 shares from 14 to 20 March 2014 at an average price of €46.51.

DSM - repurchase of shares (7-13 March 2014)

DSM repurchased 254,756 shares from 7 to 13 March 2014 at an average price of €47.40.

Royal DSM and JLL Partners Create DPx

USD 2.65 billion transaction to create global CDMO leader successfully completed.

DSM proposes appointment of new Chief Financial Officer

DSM to appoint Geraldine Matchett as Member of the Managing Board of Directors as of 1 August 2014 and as of 1 December 2014, she will become Chief Financial Officer.

DSM - repurchase of shares (27 February - 6 March 2014)

DSM repurchased 428,636 shares from 27 February to 6 March 2014 at an average price of €46.54.

DSM issues long-term €500 million bond

DSM issues €500 million 2.375% bond due 2024.

DSM resumes repurchase of shares to cover existing option plans

DSM intends to repurchase of 2,500,000 ordinary shares to cover commitments under management and personnel option plans.

DSM reports final 2013 results, increases dividend

For full year 2013 DSM delivered 18% higher EBITDA while facing challenging economic environment. In Q4 the company realized 30% higher EBITDA.

DSM finalizes repurchase of shares to cover existing option plans

DSM repurchased 874,725 shares from 17 January 2014 up to and including 21 January 2014 at an average price of €51.85 and concludes first part of program to repurchase 4-5 million shares in total.

DSM reports preliminary 2013 results, provides 2014 outlook

DSM delivered roughly 20% higher EBITDA for the full year 2013, in spite of the challenging economic environment and in Q4 realized an approximately 30% higher EBITDA.

DSM - repurchase of shares (10-16 January 2014)

DSM repurchased 245,742 shares from 10 to 16 January 2014 at an average price of €56.90.

DSM - repurchase of shares (6-9 January 2014)

DSM repurchased 112,588 shares from 6 to 9 January 2014 at an average price of €57.88.

DSM - repurchase of shares (13-19 December 2013)

DSM repurchased 154,586 shares from 13 to 19 December 2013 at an average price of €55.35.

DSM announces final terms of €300 million bond

Final Terms of the €300,000,000 1.75% Notes due 13 November 2019 adjusted to reflect investors have a put option in the event of a change of control.

DSM - repurchase of shares (6-12 December 2013)

DSM repurchased 185,761 shares from 6 to 12 December 2013 at an average price of €56.08.

DSM - repurchase of shares (29 November - 5 December 2013)

DSM repurchased 164,545 shares from 29 November to 5 December 2013 at an average price of €57.17.

Johns Hopkins Bloomberg School of Public Health awards Dean’s Medal to Royal DSM N.V.

Award recognizes DSM's global corporate leadership in efforts to mitigate food insecurity, prevent hidden hunger and promote sustainable development in low-income countries.

DSM - repurchase of shares (15-21 November 2013)

DSM repurchased 346.038 shares from 15 to 21 November 2013 at an average price of €59.06.

DSM - repurchase of shares (22-28 November 2013)

DSM repurchased 198,288 shares from 22 to 28 November 2013 at an average price of €58.39.

Royal DSM and JLL create leading pharma services company in USD 2.6 bn transaction

Global CDMO company combines DSM Pharmaceutical Products and Patheon.

DSM - repurchase of shares (6-14 November 2013)

DSM repurchased 217,727 shares from 6 to 14 November 2013 at an average price of €58.05.

DSM issues long-term €300 mln bond

DSM successfully issues €300 million 1.75% bond due 2019.

DSM announces repurchase of shares to cover existing option plans

DSM intends to repurchase 2,500,000 ordinary shares to cover commitments under management and personnel option plans.

DSM maintains positive momentum in challenging markets

Q3 EBITDA of €342 million compared to €270 million in Q3 2012. 27% improvement realized despite ongoing challenging macro-economic environment.

DSM completes acquisition of stake in Andre Pectin (China)

DSM acquires 19% equity interest in Yantai Andre Pectin Co. Ltd., a China based producer of texturing ingredients.

DSM updates financial markets at its Capital Markets Day

DSM providing review of strategic progress and update on its 2015 targets at its annual Capital Markets Day.

DSM once again among leaders in DJ Sustainability World Index

DSM once again amongst leaders in chemical industry sector in Dow Jones Sustainability World Index 2013.

DSM delivers higher profits; full year outlook unchanged

DSM reports second quarter EBITDA of €345 million compared to €290 million in Q2 2012 and €311 million in Q1 2013.

DSM to better serve Nutrition customers in Asia with acquisition of Unitech (NZ)

DSM acquires Unitech Industries Limited, a New Zealand based producer of nutritional products for both human and animal markets.

DSM CEO joins Global CEO Council to support Chinese leadership on innovation, urbanization and sustainability

Feike Sijbesma joins Global CEO Council (GCC) of the Chinese People’s Association for Friendship with Foreign Countries (CPAFFC).

DSM to contribute to new 2020 global nutrition target

DSM to help provide effective nutrition interventions to 50 million pregnant and lactating woman and children under two per year by 2020 as part of DSM’s endorsement of Global Nutrition for Growth Compact.

Royal DSM, World Vision announce partnership to nourish millions of the world's most vulnerable children

Working together to achieve lasting progress in global health and development by improving the nutritional status of mothers and children.

DSM to acquire 19% interest in Andre Pectin (China)

Agreement to acquire 19% equity interest in Yantai Andre Pectin Co. Ltd. (Andre Pectin), a China based producer of texturing ingredients.

Final dividend 2012 Royal DSM

DSM declares a dividend for the financial year 2012 of €1.50 per ordinary share of €1.50 nominal value.

DSM announces results of 2013 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 3 May 2013. Shareholders approved all resolutions on the agenda.

Annual General Meeting of Shareholders 2013

Summary of the resolutions at DSM's Annual General Meeting of Shareholders 2013.

DSM reports good start to the year in challenging environment

DSM reports first quarter EBITDA of €311 million compared to €306 million in Q1 2012 and €243 million in Q4 2012.

DSM and Rostekhnologii to cooperate on biotechnology and functional materials

Strategic partnership with Rostekhnologii (Rostec) in fields of biotechnology and functional materials.

DSM and Republic of Tatarstan sign MOU for fortified nutrition

Partnership with Ministry of Health Care of the Republic of Tatarstan aims to modernize the Republic’s public health sector through fortified nutrition.

DSM completes acquisition of Tortuga

DSM acquires Tortuga, a nutritional supplements company with a focus on pasture raised beef and dairy cattle for a total enterprise value of about €440 million.

DSM - proposed appointment to the Managing Board of Directors

DSM proposes appointing Mr. Dimitri de Vreeze to the Managing Board effective 1 September 2013.

DSM completes sale of participation in DEXPlastomers JV to Borealis

DSM sells its participation in DEXPlastomers, a 50/50 Joint Venture of DSM with affiliate of ExxonMobil Chemical, to Borealis.

DSM is positioned for strong EBITDA growth and increases dividend

DSM delivered growth across all clusters in 2012 excluding caprolactam. Nutrition represents more than 70% of total EBITDA and become high value, global business with attractive growth prospects across the full value chain.

DSM and UN WFP strengthen partnership to combat global malnutrition

Agreement extends existing partnership to 2015 to combat hidden hunger and malnutrition in the developing world.

DSM wins Corporate Steward Award 2012

Award recognizes DSM's integrated Triple P approach to creating a sustainable business and shared value with all stakeholders.

DSM CEO to receive honorary doctorate

University of Maastricht confers honor on Feike Sijbesma because of way he embodies DSM’s core value, sustainability.

DSM completes acquisition of Cargill’s cultures and enzymes business

Acquisition enables DSM to become a global tier one dairy ingredients supplier.

DSM’s sustainable supply chain management recognized

DSM awarded Sustainable Supply Chain Award 2012 for its responsible way of managing its supply chain.

DSM awarded for its integrated reporting

DSM receives three prestigious awards in the Netherlands for its 2011 Integrated Annual Report.

DSM to sell participation in DEXPlastomers JV to Borealis

Agreement with Borealis AG reached for sale of DEXPlastomers V.o.F and DSM's LldPE Compact Solution Technology.

DSM reports solid Q3 results despite weak economic conditions

DSM continues to generate good results mainly driven by Nutrition cluster and make good progress towards strategic goals with purchase of Tortuga and Cargill’s cultures and enzymes business.

DSM to acquire Cargill’s cultures and enzymes business

DSM to acquire Cargill’s cultures and enzymes business in an all cash transaction for a total enterprise value of €85 million.

DSM updates market on strategy progress at Capital Markets Days

DSM updates financial community at its annual Capital Markets Days on progress made with its DSM in Motion: driving focused growth strategy.

DSM appoints new President DSM Nutritional Products

Chris Goppelsroeder appointed President and CEO DSM Nutritional Products effective 1 January 2013.

DSM in exclusive discussions to acquire Cargill’s cultures and enzymes business

DSM in exclusive discussions with Cargill which may, or may not result in DSM's acquisition of Cargill’s cultures and enzymes business.

DSM amongst leaders in Dow Jones Sustainability World Index

DSM again among leaders in chemical industry sector in the Dow Jones Sustainability World Index 2012.

DSM to acquire Tortuga to strengthen animal nutrition business

Definitive agreement to acquire Tortuga Companhia Zootécnica Agrária (Tortuga) in all cash transaction for total enterprise value of about €465 million.

DSM reports robust Q2 in challenging environment

Life Sciences cluster accounts for around 70% of Q2 EBITDA offsetting weakness caused by caprolactam in Materials Sciences. Other Materials Sciences businesses improve.

DSM completes acquisition of Ocean Nutrition Canada and expands its Nutritional Lipids growth platform

DSM acquires Ocean Nutrition Canada, leading global provider of fish-oil derived nutritional products to dietary supplement and food and beverage markets for a total enterprise value of C$540 million.

DSM completes acquisition of Kensey Nash and strengthens its biomedical business

DSM completes acquisition of Kensey Nash for a total enterprise value of approximately $360 million.

DSM tender offer for Kensey Nash is successful; acquisition expected to close within next few days

Tender offer to purchase all outstanding shares of common stock of Kensey Nash Corporation at a price of $38.50 per share successful.

DSM announces expiration of waiting period under Hart-Scott-Rodino Act

Expiration of mandatory waiting period under Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for previously announced tender offer for all outstanding shares of common stock of Kensey Nash Corporation.

DSM enzymes for cellulosic ethanol qualified by DONG Energy

DSM qualified as supplier of enzymes for DONG Energy - Inbicon’s wheat straw to cellulosic ethanol process.

DSM commences tender offer for Kensey Nash

DSM commences previously announced tender offer for all outstanding shares of common stock of Kensey Nash at a price of $38.50 per share.

DSM to acquire Ocean Nutrition Canada to expand its Nutritional Lipids growth platform

Definitive agreement with Clearwater Fine Foods and funds managed by Richardson Capital to acquire Ocean Nutrition Canada for a total enterprise value of C$540 million.

DSM appoints two new Supervisory Board members

Annual General Meeting of Shareholders approves appointing Mrs. Victoria Haynes and Mrs. Eileen Kennedy as Supervisory Board members.

Final dividend 2011 Royal DSM

DSM declares a dividend for 2011 of €1.45 per ordinary share of €1.50 par value.

DSM announces results of 2012 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 11 May 2012. Shareholders approved all resolutions on the agenda.

Annual General Meeting of Shareholders 2012

Summary of the resolutions at DSM's Annual General Meeting of Shareholders 2012.

DSM reports positive start to the year with robust Q1 results

In a challenging business environment, DSM continued to make good progress in Q1 and the robust results represent a positive start to 2012.

DSM agrees to acquire Kensey Nash to strengthen its biomedical business

DSM will acquire all outstanding shares of common stock of Kensey Nash through a cash tender offer, followed by a merger with a subsidiary of DSM, for $38.50 in cash per share for total enterprise value of approximately $360 million.

DSM announces management changes

Jos Op Heij new Senior Vice President Corporate Control and Accounting, Hans Vossen new VP Corporate Treasury & Dave Huizing new VP Investor Relations.

DSM acquires food enzymes business and key technology from Verenium

DSM acquires certain assets, licenses and other agreements in the area of food enzymes and oilseed processing from Verenium for a total consideration including transaction and related expenses of $37 million.

DSM reports another strong year and increases dividend

2011 was another strong year for DSM despite challenges of global economy, adverse currency movements and high raw material costs and increases dividend for second consecutive year.

DSM appoints new General Counsel

Cees Los joins DSM as General Counsel and Director Legal Affairs as of 15 April 2012.

DSM and POET to make advanced biofuels a reality by 2013

Joint Venture to commercially demonstrate and license cellulosic bio-ethanol, the next step in the development of biofuels, based on their proprietary and complementary technologies.

DSM reports strong Q3 results

Q3 2011 EBITDA from continuing operations €339 million, 26% ahead of Q3 2010, outlook remains unchanged: 2011 is expected to be a strong year with further progress towards achieving 2013 targets.

DSM finalizes repurchase of shares to cover existing option plans

DSM repurchased 502,990 shares from 27 October to 2 November 2011 at an average price of €37.33 and concluded the program to repurchase 4,000,000 shares.

DSM – repurchase of shares (20–26 October 2011)

DSM repurchased 471,588 shares from 20 to 26 October 2011 at an average price of €36.81.

DSM sells majority stake in TCG to MocoLabs

TCG developed OtCM™ system to monitor compliance with drug therapy.

DSM – repurchase of shares (13–19 October 2011)

DSM repurchased 545,760 shares from 13 to 19 October 2011 at an average price of €37.15.

DSM - repurchase of shares (6-12 October 2011)

DSM repurchased 391,817 shares from 6 to 12 October 2011 at an average price of €35.51.

DSM proposes two new members of Supervisory Board

DSM Supervisory Board proposes appointing Mrs. Victoria Haynes and Mrs. Eileen Kennedy as Supervisory Board members.

DSM – repurchase of shares (29 September – 5 October 2011)

DSM repurchased 519,526 shares from 29 September to 5 October 2011 at an average price of €32.42.

DSM completes acquisition of majority share in China-based UHMWPE fiber manufacturer

DSM acquires Shandong ICD High Performance Fiber Co. Ltd. (ICD), based in Laiwu, Shandong province, China.

DSM updates market on strategy progress at Capital Markets Days

DSM updates investment community on progress made with strategy marking the shift from an era of intensive portfolio transformation to a strategy for the coming years of maximizing sustainable and profitable growth of ‘the new DSM’.

DSM – repurchase of shares (22-28 September 2011)

DSM repurchased 523,199 shares from 22 to 28 September 2011 at an average price of €31.49.

DSM renews €500 million credit facility

Unsecured credit facility of €500 million is for a minumum term of 5 years and a maximum term of 7 years.

DSM – repurchase of shares (15-21 September 2011)

DSM repurchased 404,055 shares from 15 to 21 September 2011 at an average price of €32.52.

DSM reports fatal accident at Augusta (Georgia, USA)

On 13 September 2011 a fatal accident took place on DSM property in Augusta (Georgia, USA), in which one contractor lost his life. DSM deeply regrets this tragic accident and expresses its sympathy to the victim’s family.

DSM – repurchase of shares (7-14 September 2011)

DSM repurchased 641,065 shares from 7 to 14 September 2011 at an average price of €31.84.

DSM to sell Personalized Nutrition to Viocare

DSM Personalized Nutrition’s corporate wellness business will become part of Viocare’s operations.

DSM continues leadership in Dow Jones Sustainability World Index

DSM once again retained its number one position in the chemical industry sector in the Dow Jones Sustainability World Index.

DSM announces repurchase of shares to cover existing option plans

DSM intends to repurchase 4,000,000 ordinary shares to cover commitments under management and personnel option plans.

DSM and Sinochem Group establish global anti-infectives joint venture

Sinochem Group has taken a 50% equity interest in DSM Anti-Infectives for total cash consideration of €210 million on a cash and debt-free basis with 1 January 2011 as effective date.

DSM announces exchange ratio interim stock dividend 2011

Exchange ratio for the dividend in shares has been determined at 1 new ordinary share for every 72.338 existing ordinary shares.

DSM appoints new Executive Vice President Corporate Strategy & Acquisitions

Philip Eykerman will join DSM as Executive Vice President Corporate Strategy & Acquisitions.

DSM reports strong Q2 results with solid growth

Q2 EBITDA from continuing operations €339 million, above both Q2 2010 and Q1 2011.

Joint statement by DSM and Nutreco regarding Provimi

DSM and Nutreco confirm they have decided to jointly explore the possibility to acquire Provimi.

DSM successfully acquires 51% stake in AGI Corporation (Taiwan)

DSM acquires interest in manufacturer of environmentally friendly UV-curable resins.

DSM and KuibyshevAzot commence strategic cooperation in Russia

Ventures cover marketing and production of engineering plastics compounds in Russia.

DSM completes acquisition of Vitatene S.A.U.

Acquisition of Vitatene allows DSM to strengthen the natural carotenoids offerings of its nutrition business as consumer demand for natural products continues to grow.

DSM strengthens yeast technology leadership for 2G biofuels

Acquisition adds new yeast and enzyme technologies for second generation biofuels.

DSM provides information on optional stock dividend

Exchange ratio for the dividend in shares has been determined at 1 new ordinary share for every 48.077 existing ordinary shares.

DSM finalizes repurchase of shares to cover existing option plans

DSM repurchased 264,319 shares from 13 to 16 May 2011 at an average price of €46.56 and concluded the program to repurchase 5,000,000 shares.

DSM – repurchase of shares (6-12 May 2011)

DSM repurchased 502,059 shares from 6 to 12 May 2011 at an average price of €46.05.

DSM to acquire Vitatene S.A.U. to expand position in natural carotenoids

Acquisition allows DSM to strengthen the natural carotenoids offerings of its nutrition business as consumer demand for natural products continues to grow.

Feike Sijbesma recognized with George Washington Carver Award

Feike Sijbesma received award in recognition of his outstanding contribution to development and innovation in industrial biotechnology.

DSM and Roquette to open commercial scale bio-based succinic acid plant in 2012

New chemical building block offers bio-based alternative.

DSM – repurchase of shares (29 April - 5 May 2011)

DSM repurchased 601,953 shares from 29 April to 5 May 2011 at an average price of €45.78.

DSM completes sale of DSM Elastomers to LANXESS

DSM completes sale of DSM Elastomers to LANXESS for €310 million on a cash and debt-free basis.

DSM tenders Danisco shareholding

DSM has tendered its 4.95% stake in Danisco to DuPont.

DSM – repurchase of shares (26-28 April 2011)

DSM repurchased 435,987 shares from 26 to 28 April 2011 at an average price of €45.33.

Final dividend 2010 Royal DSM

DSM declares dividend for 2010 of €1.35 per ordinary share of €1.50 par value.

DSM announces results of 2011 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 28 April 2011. Shareholders approved all resolutions on the agenda.

Annual General Meeting of Shareholders 2011

Summary of the resolutions at DSM's Annual General Meeting of Shareholders 2011.

DSM reports very strong Q1 2011 continuing its positive momentum

Q1 EBITDA from continuing operations up 14% to €325 million.

DSM announces new President of DSM Netherlands

DSM intends to appoint Mr. Atzo Nicolaï (1960), currently Member of the Dutch House of Representatives (“Tweede Kamer der Staten-Generaal”) with effect from 1 June 2011.

DSM – repurchase of shares (15-21 April 2011)

DSM repurchased 368,294 shares from 15 to 21 April 2011 at an average price of €42.70.

DSM – repurchase of shares (8-14 April 2011)

DSM repurchased 326,090 shares from 8 to 14 April 2011 at an average price of €43.53.

DSM – repurchase of shares (1-7 April 2011)

DSM repurchased 376,582 shares from 1 to 7 April 2011 at an average price of €43.97.

DSM provides comparative 2010 figures in line with new reporting structure

DSM will implement changes in the presentation of its financial results as from Q1 2011.

DSM – repurchase of shares (25-31 March 2011)

DSM repurchased 349,822 of its own shares from 25 to 31 March 2011 at an average price of €43.34.

DSM – repurchase of shares (18-24 March 2011)

DSM repurchased 331,532 shares from 18 to 24 March 2011 at an average price of €42.33.

DSM – repurchase of shares (11-17 March 2011)

DSM repurchased 479,895 shares from 11 to 17 March 2011 at an average price of €41.13.

DSM – repurchase of shares (4-10 March 2011)

DSM repurchased 499,687 shares from 4 to 10 March at an average price of € 43.49.

DSM – repurchase of shares (24 February - 3 March 2011)

DSM repurchased 463,780 shares from 24 February to 3 March 2011 at an average price of €42.74.

DSM announces partnership for specialty resins with Kemrock Industries in India

Partnership with Kemrock Industries in India for the production of specialty composite resins in India.

DSM completes acquisition of Martek; adding new Nutrition growth platform

Acquisition adds new growth platform for healthy and natural food ingredients, focused on Omega-3 DHA and Omega-6 ARA.

DSM successfully completes tender offer for Martek and expects to complete acquisition today

DSM successfully completes subsequent offering period to its all-cash tender offer.

DSM joint venture to build world class composite resins facility in China

Jinling DSM Resins Co., Ltd. (JDR) will invest approximately €50 million in a new production facility for composite resins in Nanjing, China.

DSM – proposed appointment to the Managing Board of Directors

Supervisory Board proposes appointing Mr. Stefan Doboczky to DSM's Managing Board with effect from 1 May 2011.

DSM reports strong 2010 results and proposes dividend increase to €1.35

Full-year operating profit continuing operations up 74% to €752 million, dividend increase of 12.5% per ordinary share proposed.

DSM marks its transformation with new brand

Royal DSM N.V today introduces a new company brand: Bright Science. Brighter Living™. The new brand is symbolic of the transition to the ‘new’ DSM.

DSM announces repurchase of shares to cover existing option plans

DSM intends to repurchase 5,000,000 ordinary shares to cover commitments under management and personnel option plans.

DSM announces new Supervisory Board chairman

DSM Supervisory Board has appointed Rob Routs as its new Chairman.

DSM tender offer for Martek Biosciences Corporation is successful

Tender offer to purchase all outstanding shares of common stock of Martek Biosciences Corporation successful.

DSM announces receipt of final competition clearance for acquisition of Martek

Counsel of the National Competition Commission approves acquisition.

DSM acquires majority share in UHMWPE fiber manufacturer in China

DSM to acquire the majority shareholding in Shandong ICD High Performance Fibre Co Ltd. based in Laiwu, China.

DSM provides 2009 comparative figures

DSM will use new P&L from the publication of the full year 2010 results onwards.

DSM announces expiration of waiting period under Hart-Scott-Rodino Act

Waiting period for DSM's offer for all outstanding shares of Martek Biosciences Corporation at a price of $31.50 per share closes.

DSM and USAID partnership to meet nutritional challenges of developing world

DSM and United States Agency for International Development (USAID) to collaborate and collectively work to meet the nutritional challenges presented in the developing world.

DSM and KuibyshevAzot announce strategic cooperation in Russia

DSM Engineering Plastics to enter two joint ventures with KA.

DSM commences tender offer for Martek Biosciences Corporation

DSM commences tender offer for all outstanding shares of common stock of Martek Biosciences Corporation at a price of $31.50 per share.

DSM discloses shareholding in Danisco

DSM holds a 4.95% stake in Danisco which has been acquired some years ago.